Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma

  title={Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma},
  author={N. Ding and Xiaosong Li and Yunfei Shi and L. Ping and Lina Wu and K. Fu and L. Feng and X. Zheng and Y. Song and Z. Pan and J. Zhu},
  pages={15122 - 15136}
  • N. Ding, Xiaosong Li, +8 authors J. Zhu
  • Published 2015
  • Medicine
  • Oncotarget
  • The B-cell receptor (BCR) signaling pathway has gained significant attention as a therapeutic target in B-cell malignancies. Recently, several drugs that target the BCR signaling pathway, especially the Btk inhibitor ibrutinib, have demonstrated notable therapeutic effects in relapsed/refractory patients, which indicates that pharmacological inhibition of BCR pathway holds promise in B-cell lymphoma treatment. Here we present a novel covalent irreversible Btk inhibitor PLS-123 with more potent… CONTINUE READING
    16 Citations

    Figures, Tables, and Topics from this paper.

    The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
    • 28
    • PDF
    The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    • 28
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    • 1
    • PDF
    Targeting Btk with ibrutinib inhibit gastric carcinoma cells growth.
    • 16
    • PDF
    Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents.
    • L. Wang, J. Zhao, +8 authors X. Ma
    • Chemistry, Medicine
    • European journal of medicinal chemistry
    • 2017
    • 19


    Ibrutinib and novel BTK inhibitors in clinical development
    • 154
    Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
    • 41
    The B-cell receptor signaling pathway as a therapeutic target in CLL.
    • 316
    • PDF
    SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
    • 289
    Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
    • 410
    The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
    • 993
    • PDF
    Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    • R. Advani, J. Buggy, +12 authors N. Fowler
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2013
    • 820